BILL ANALYSIS                                                                                                                                                                                                    Ó



                                                                            



           ----------------------------------------------------------------- 
          |SENATE RULES COMMITTEE            |                        SCR 58|
          |Office of Senate Floor Analyses   |                              |
          |1020 N Street, Suite 524          |                              |
          |(916) 651-1520         Fax: (916) |                              |
          |327-4478                          |                              |
           ----------------------------------------------------------------- 
           
                                           
                                    THIRD READING


          Bill No:  SCR 58
          Author:   Beall (D)
          Amended:  As introduced
          Vote:     21

           
          SUBJECT  :    Restless Legs Syndrome/Willis-Ekbom Disease  
          Awareness Day

           SOURCE  :     Author


           DIGEST  :    This resolution proclaims September 23, 2013, as  
          Restless Legs Syndrome/Willis-Ekbom Disease Awareness Day in  
          California.

           ANALYSIS  :    This resolution makes the following legislative  
          findings:

          1. Restless Legs Syndrome/Willis-Ekbom disease is a neurological  
             disorder characterized by unpleasant sensations in the legs  
             and a distressing, irresistible urge to move them.

          2. An estimated 10 million adults in the United States, totaling  
             3% of our country, and millions of others worldwide have been  
             affected by Restless Legs Syndrome/Willis-Ekbom disease, a  
             disease for which there is no known cure and is difficult to  
             diagnose. 

          3. Symptoms typically include an urge to move the legs, caused  
             by uncomfortable and unpleasant sensations in the legs,  
             presenting or worsening in the evening or night.

                                                                CONTINUED





                                                                     SCR 58
                                                                     Page  
          2

          4. Restless Legs Syndrome/Willis-Ekbom disease has an impact on  
             sleep, concentration, and work productivity; with 68.6% of  
             patients needing more than 30 minutes to initiate sleep and  
             60.1% waking three or more times per night; with 49.7% of  
             patients reporting that symptoms adversely affect next day  
             concentration.  Patients with moderate to severe Restless  
             Legs Syndrome/Willis-Ekbom disease have an overall mean loss  
             of workplace productivity of one day per 40-hour workweek. 

          5. The Restless Legs Syndrome Foundation, a nonprofit  
             organization, and other groups around our country have joined  
             together to promote Restless Legs Syndrome/Willis-Ekbom  
             disease awareness and support, including improved education,  
             diagnosis, research, and treatment.

          This resolution proclaims September 23, 2013, as Restless Legs  
          Syndrome/Willis-Ekbom Disease Awareness Day in California and  
          the Restless Legs Syndrome Foundation is urging patients, their  
          supporters, health care providers, and the general public to  
          demonstrate their caring by sharing the road on which patients  
          walk, the facts about Restless Legs Syndrome/Willis-Ekbom  
          disease, and the growing awareness of the etiology of this  
          disorder and treatments.

           FISCAL EFFECT  :    Fiscal Com.:  No

           SUPPORT  :   (Verified  7/3/13)

          Stanford Hospital and Clinics
          UCB, Inc.


          JL:k  7/3/13   Senate Floor Analyses 

                           SUPPORT/OPPOSITION:  SEE ABOVE

                                   ****  END  ****